New shot aims to prevent dangerous clots in High-Risk patients
NCT ID NCT07430397
First seen Feb 27, 2026 · Last updated May 22, 2026 · Updated 16 times
Summary
This early-stage study tests a single injection of CITY-FXI, a drug designed to lower a clotting factor in the blood. It includes healthy adults and those with Factor V Leiden or prothrombin G20210A mutations, which increase clot risk. The main goal is to check safety and how the drug works in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FACTOR V LEIDEN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Richmond Pharmacology
RECRUITINGLondon, SE1 1YR, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.